[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"c-reactive-protein\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:c-reactive-protein":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100512893","assessing-the-value-of-avocados-on-glycemic-control-in-type-2-diabetes-100512893",false,"NCT05958368","Assessing the Value of Avocados on Glycemic Control in Type 2 Diabetes","The Effects of Hass Avocados on Glycemic Control in Persons With Type 2 Diabetes: A Randomized Controlled Crossover Trial","AVOCADO-T2D","Inclusion Criteria:\n\n* Participant reported diagnosis of Type 2 diabetes\n* HbA1c between 5.7%-11% (inclusive) and \u002F or fasting blood glucose of ≥ 100 mg\u002FdL\n* BMI 27-50 kg\u002Fm2 (inclusive)\n* Age range - 18 - 65 years (inclusive)\n* On stable regimen of all medications (including diabetes) for at least 3 months (brief regimens of medications such as antibiotics, steroids, etc. are permitted)\n* Willing to follow all requirements of study protocol including blood draws\n* Under the care of a physician who will be responsible for managing the subject's diabetes\n* Willing to give release to provide their treating MD with information about the trial\n\nExclusion Criteria:\n\n* Not willing or unable to consume study foods including avocados\n* Participation in a weight control program within the past 3 months or weight loss of ≥ 5 kg in the previous 3 months\n* Taking prescription or OTC weight loss medications within last 4 weeks\n* History of a surgical procedure for weight loss in last 5 years (e.g. gastroplasty, gastric by-pass, gastrectomy or partial gastrectomy, adjustable banding, gastric sleeve)\n* History of major surgery within three months of enrollment\n* Type 1 diabetes, insulin dependent type 2 diabetes, thiazolidinediones (including rosiglitazone and pioglitazone)\n* Renal insufficiency consisting of potassium over 5.5 (mmol\u002FL) on a non-hemolyzed specimen, or a creatinine over 2.5 mg\u002FdL\n* Bilirubin over 3 (mg\u002FdL) or an albumin less than 3 (g\u002FdL)\n* ALT \\> 3 (IU\u002FL) times the upper limit of normal (normal range is 7-56)\n* Evidence of more than 1 severe hypoglycemic event (episode requiring emergency medical services) in the past 12 months, unless the participant's treating physician provides written clearance for participation.\n* Those on higher doses of diuretics (furosemide 40mg or higher or comparable)\n* Unstable heart disease (an ongoing workup or treatment for a cardiac symptom such as unstable angina, coronary ischemia)\n* Presence of implanted cardiac defibrillator\n* Blood pressure ≥180\u002F100 mm Hg. If a potential participant has a BP above the inclusion criteria it is acceptable to re-test this potential participant within one week of the original test.\n* Thyroid disease for which the participant is untreated or has had treatment changed within the last 6 months. History of thyroid disease or current thyroid disease treated with a stable medication regimen for at least 6 months is acceptable\n* Uncontrolled gastrointestinal disorders including chronic malabsorptive conditions, peptic ulcer disease, Crohn's disease, chronic diarrhea, or active gallbladder disease\n* Current cancer or cancer treatment, or a history of cancer or cancer treatment within the last 3 years. Persons with successfully resected non-melanoma carcinoma of the skin may be enrolled.\n* Dementia, psychiatric illness, or substance abuse that may interfere with adherence (e.g., illness that is currently unstable or resistant to first-line therapy; substance abuse in the past year)\n* Women who are pregnant, lactating, trying to become pregnant or unwilling to use an effective means of birth control\n* Currently consuming \\>14 alcoholic drinks (1 drink = 12 fl oz beer, 4 fl oz wine or 1.5 fl oz liquor) per week and unwilling to stop intake during study participation\n* Participation in another clinical trial within 30 days prior to enrollment\n* Any other condition or factor which in the opinion of the study physician or investigator makes it inadvisable for the candidate to participate in the trial",true,"ALL","18 Years","65 Years",{"count":22,"type":23},48,"ESTIMATED","INTERVENTIONAL",[26],"NA","The objective of this study is to assess the effects of Hass Avocados on glycemic control. The investigators hypothesize that Hass Avocado consumption will reduce fasting blood sugar compared to an isocaloric amount of other fruit during controlled feeding.",[29,30,31,32,33,34],"Diabetes Mellitus, Type 2","Insulin","Fructosamine","C-Reactive Protein","Glucose","Overweight and Obesity","RECRUITING","2025-07-28",{"date":38,"type":39},"2025-07-31","ACTUAL",{"date":41,"type":39},"2023-10-10",{"date":43,"type":23},"2026-12-15",{"name":45,"class":46},"Pennington Biomedical Research Center","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":24,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":47},"100599814","efficacy-and-safety-of-resveratrol-in-patients-with-rheumatoid-arthritis-100599814","NCT07089381","Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.","Inclusion Criteria:\n\n* Adult patients \\> 18 years old\n* Established diagnosis of RA according to American College of Rheumatology\u002FEuropean league Against Rheumatism (ACR\u002FEULAR) 2010 criteria (Aletaha et al., 2010), presented with moderate to high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n* Patients receiving stable regimen of one or more csDMARDs for at least the past 3 months.\n* RA Patients with Moderate or high disease activity identified as disease activity score-28 based on C-reactive protein (CRP) levels (DAS-28-CRP) \\>3.2.\n\nExclusion Criteria:\n\n* Patients receiving biologic DMARDs therapy for RA\n* Patients taking any other anti-inflammatory drugs\n* Patients taking any other antioxidants\n* Pregnant and lactating women\n* Other rheumatological, inflammatory diseases or malignancies\n* Smokers\n* Thyroid illnesses\n* Patients with impaired liver functions (liver transaminases level ≥ three times upper normal limits), impaired kidney functions (estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin)",{"count":55,"type":23},118,[26],"The aim of the current study is to evaluate the effects of resveratrol on the clinical outcome(s) of patients with moderate rheumatoid arthritis.\n\nObjectives :\n\n1. To investigate the effects of Resveratrol on inflammation and oxidative stress by measuring:\n\n   * Serum Sirtuin 1(SIRT1)\n   * Serum Myeloperoxidase (MPO)\n   * Serum C-reactive protein (CRP)\n2. To investigate the effects of Resveratrol on disease activity by measuring the disease activity (DAS28 score).\n3. To investigate the effect of Resveratrol on improving the quality of life using the Health Assessment Questionnaire Disability index (HAQ-DI).\n4. To assess any adverse effects related to Resveratrol.\n\nPatients:\n\nEligible patients (no=118) will be randomly assigned in a 1:1 ratio to one of two groups:\n\n1. Control group: 59 patients will receive the standard treatment for management of RA for 3 months.\n2. Resveratrol group: 59 patients will receive the standard treatment for management of RA in addition to Resveratrol 1 gm daily, (Organix Egypt) (given as one 1000 mg tablets once daily) for 3 months.",[59,60,61,62,63,64,65,66,67],"Rheumatic Arthritis","Rheumatoid Arthritis (RA) Prevention","Inflamation","Antioxidant","Anti Oxidative Stress","Anti Aging","C Reactive Protein","Methotrexate","Quality of Life Outcomes","2025-07-21",{"date":36,"type":39},{"date":71,"type":23},"2025-08-01",{"date":73,"type":23},"2026-06-01",{"name":75,"class":46},"Ain Shams University",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":24,"phases":86,"briefSummary":87,"conditions":88,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100434641","crp-apheresis-in-stemi-100434641","NCT04939805","CRP Apheresis in STEMI","Selective C-reactive Protein Apheresis in ST-elevation Myocardial Infarction","Inclusion Criteria:\n\n1. Diagnosis of first acute STEMI in accordance with the European Society of Cardiology (ESC) Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation\n2. Symptoms consistent with STEMI with beginning greater than 30 minutes but less than 12 hours prior to primary percutaneous coronary intervention (PCI)\n3. CRP elevation of ≥7 mg\u002Fl measured between 6 to 16 hours after primary PCI\n4. Eligible for primary PCI\n5. Age ≥18 years\n6. Written informed consent\n\nExclusion Criteria:\n\n1. Prior acute myocardial infarction, coronary artery bypass surgery or PCI.\n2. Persistent hemodynamic instability (Killip class \\>2 including cardiogenic shock) or resuscitated cardiac arrest not allowing a CMR scan.\n3. The patient is febrile (temperature \\>38°C) or has experienced an acute infection with fever in the last 14 days.\n4. CRP \\>15 mg\u002Fl at time of hospital admission.\n5. Chronic inflammatory disease.\n6. Known history of severe hepatic failure\n7. Chronic kidney disease with a creatinine clearance \\\u003C30ml\u002Fmin.\u002F1.73m²\n8. Contraindication to CMR.\n9. Pre-STEMI life expectancy of \\\u003C1 year\n10. Participation in another interventional trial\n11. Limited possibility to join the follow-up examinations (e.g. patient lives abroad)\n12. Pregnancy","85 Years",{"count":85,"type":23},202,[26],"Background: In patients with acute ST-elevation myocardial infarction (STEMI), the amount of infarcted myocardium (infarct size) is known to be a major predictor for adverse remodeling and recurrent adverse cardiovascular events. Effective cardio-protective strategies with the aim of reducing infarct size are therefore of great interest. Local and systemic inflammation influences the fate of ischemic myocardium and thus, adverse remodeling and clinical outcome. C-reactive protein (CRP) also acts as a potential mechanistic mediator that adversely affects the amount of irreversible myocardial tissue damage after acute myocardial infarction.\n\nObjective: The main objectives of the current study are to investigate the efficacy of selective CRP apheresis, using the PentraSorb®-CRP system, as an adjunctive therapy to standard of care for patients with acute STEMI treated with primary PCI.\n\nDesign: Investigator-initiated, prospective, randomized, open-label (outcome assessors masked), controlled, multicenter, two group trial with a two-stage adaptive design.\n\nInnovation: Selective CRP apheresis offers potential to decrease infarct size and consequently improve outcome after PCI for STEMI. This is the first randomized trial investigating the impact of selective CRP apheresis on infarct size in post-STEMI patients. In perspective, the study design allows furthermore to collect robust evidence for the design of a definitive outcome study.",[89,32,90,91],"ST Elevation Myocardial Infarction","Apheresis","Myocardial Injury",[93],"Cardiac magnetic resonance imaging","2025-05-06",{"date":96,"type":39},"2025-05-09",{"date":98,"type":39},"2021-04-01",{"date":100,"type":23},"2025-08-31",{"name":102,"class":46},"Medical University Innsbruck",5]